JOIN THE EFFORT

UPCOMING WEBINAR

The Target 2035 webinars highlight relevant research topics with a mixture of talks and discussions by prominent scientific leaders and young scientists giving their perspectives and demonstrating the latest enabling technologies.

Recordings of past webinars are available HERE

Targeting Deubiquitinases for Therapeutic Benefit

September 20, 2022, 10:00 am EDT / 4:00 pm CEST

Registration Outlook online ICS

Program

Host & Moderator :
Ingrid Wertz, Bristol Myers Squibb

10 min
Ingrid Wertz, Bristol Myers Squibb
Introducing Deubiquitinases
40 min
Sara Buhrlage & Anthony Varca, Dana-Farber Cancer Institute
Targeting Deubiquitinases for Therapeutic Benefit
10 min
Moderated by Ingrid Wertz, Bristol Myers Squibb
Audience Q&A

BIO SKETCHES

Headshot of Ingrid Wertz

Ingrid Wertz (Bristol Myers Squibb)

Ingrid Wertz is the executive director of Protein Homeostasis Center of Excellence at BMS. She and her team are responsible for developing protein degrader medicines for patients in need by harnessing degradation systems naturally present within the human body. Their aim is to specifically target and eliminate disease-relevant proteins that have been largely undruggable. Prior to joining Bristol Myers Squibb, Ingrid was a principal scientist in the departments of Discovery Oncology and Early Discovery Biochemistry at Genentech, where she led the company’s degrader platform aimed at co-opting ubiquitin system enzymes for therapeutic benefit.

Read more

Headshot of Sara Buhrlage

Sara Buhrlage (Dana-Farber Cancer Institute)

Sara Buhrlage is heading a cancer chemical biology lab at the DFCI. Her lab has established an integrated DUB-focused platform comprised of DUB-targeted libraries with novel scaffolds and chemotypes and a suite of established and novel biochemical and chemoproteomic assays that has accelerated development of selective probes and annotation of function and translational potential for multiple DUBs. The group is now building on these successes to generate a deep bench of inhibitor focused projects as well as expanding the platform through innovation in DUB ligand mechanisms of action and DUB-focused technologies. 

Read more